Is xgeva for bones?

Is Xgeva used for bone conditions?

Xgeva (denosumab) is a monoclonal antibody given as a subcutaneous injection. It works by blocking RANKL, a protein that signals the body to break down bone. This reduces bone loss and lowers the chance of fractures in people with certain cancers or osteoporosis.

What cancers does it treat?

Doctors use Xgeva to prevent skeletal-related events in adults with bone metastases from solid tumors and in patients with multiple myeloma. These events include pathologic fractures, spinal cord compression, and the need for radiation or surgery to bone.

How does it differ from Zometa?

Zometa (zoledronic acid) is an intravenous bisphosphonate. Xgeva is a RANKL inhibitor given every four weeks as an injection under the skin. Patients who cannot tolerate bisphosphonates or have reduced kidney function often receive Xgeva instead.

When does the Xgeva patent expire?

The key U.S. composition-of-matter patent for denosumab expires in 2025, with some formulation and method-of-use patents extending to 2027. After these dates, biosimilar versions may enter the market, though litigation could delay launch.

Who makes Xgeva?

Amgen manufactures and markets Xgeva. The company also sells Prolia, which contains the same active ingredient but is approved at a lower dose for postmenopausal osteoporosis and other non-oncology indications.

What side effects do patients report most?

Common side effects include fatigue, nausea, and low blood calcium. A rarer but serious risk is osteonecrosis of the jaw, especially in patients with poor dental health or recent dental procedures. Regular dental check-ups are advised before and during treatment.

Can Xgeva be given with other cancer drugs?

Yes. It is often combined with chemotherapy, hormone therapy, or targeted agents. The schedule remains every four weeks regardless of the accompanying regimen.

How long do patients stay on Xgeva?

Treatment duration depends on the underlying cancer and response. In metastatic disease, many patients continue Xgeva as long as they tolerate it and still face a fracture risk. Some stop after two years if bone metastases are stable and calcium levels are normal.

DrugPatentWatch.com